(redirected from Epifibatide)


an inhibitor of platelet aggregation used for prevention of thrombosis in patients with acute coronary syndrome or undergoing certain percutaneous coronary procedures; administered intravenously.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.



Pharmacologic class: Platelet aggregation inhibitor

Therapeutic class: Antiplatelet agent

Pregnancy risk category B


Decreases platelet aggregation by binding to platelet-receptor glycoprotein, preventing binding of fibrinogen to platelets, which causes thrombus formation


Injection: 10-ml vial (2 mg/ml), 100-ml vial (0.75 mg/ml)

Indications and dosages

Acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction)

Adults: 180 mcg/kg I.V. bolus over 1 to 2 minutes, followed by a continuous infusion of 2 mcg/kg/minute for up to 72 hours

Prevention of thrombosis related to percutaneous coronary intervention (PCI)

Adults: 180 mcg/kg I.V. bolus immediately before PCI, then a continuous infusion of 2 mcg/kg/minute, followed by a second 180-mcg/kg bolus 10 minutes after first bolus. Continue infusion until discharge or for up to 24 hours.

Dosage adjustment

• Renal impairment


• Hypersensitivity to drug or its components

• Severe hypertension

• Bleeding disorders or evidence of active abnormal bleeding within previous 30 days

• Renal dialysis

• Recent cerebrovascular accident

• Recent surgery

• Current or planned administration of another parenteral Gp IIb/IIIa inhibitor


Use cautiously in:

• renal insufficiency

• creatinine level below 2 mg/dl

• platelet count below 100,000/mm3

• elderly patients

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


• Withdraw single bolus dose from 10-ml vial into syringe, and give by I.V. push over 1 to 2 minutes. Follow single I.V. bolus dose with continuous I.V. infusion given undiluted from 100-ml vial spiked with infusion set connected to infusion control device.

• Don't administer through same I.V. line as furosemide.

Adverse reactions

CNS: headache, dizziness, asthenia, syncope

CV: hypotension

GI: nausea, diarrhea, constipation

GU: hematuria

Hematologic: bleeding tendency, thrombocytopenia

Skin: flushing

Other: bleeding at femoral access site


Drug-drug. Clopidogrel, dipyridamole, nonsteroidal anti-inflammatory drugs, oral anticoagulants, thrombolytics, ticlopidine: increased risk of bleeding Other platelet aggregation inhibitors: serious bleeding

Drug-diagnostic tests. Platelets: decreased count

Drug-herbs. Most commonly used herbs: increased anticoagulant effect of eptifibatide

Patient monitoring

• Monitor vital signs and assess cardiovascular status, especially for syncope and hypotension.

• Monitor coagulation studies, CBC, and platelet count. Watch for signs and symptoms of abnormal bleeding or bruising and hematuria.

• Check carefully for bleeding at all sites of invasive procedures, particularly femoral access site.

Patient teaching

• Tell patient drug may cause serious adverse effects but can help prevent a heart attack. Reassure him that he'll be closely monitored during therapy.

Instruct patient to immediately report fainting or abnormal bruising or bleeding.

• Teach patient safety measures to avoid bruising or bleeding.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


Integrilin® Cardiology An antithrombotic GP IIb/IIIa receptor antagonist that blocks fibrinogen and von Willebrand factor from binding to the surface of activated platelets
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Patients who received a IIb/IIIa inhibitor during initial treatment were treated with either epifibatide or tirofiban.